Study Overview

The purpose of this study is to:

  • Evaluate the pharmacokinetics (PK) of the research study drug, tedizolid phosphate (TZD), also known as SIVEXTRO, and its active metabolite tedizolid in subjects with known or suspected gram positive infection.
  • Test the safety and tolerability of intravenous (IV) or oral TZD administration in pediatric subjects. 

This is a research study to test an investigational drug that has not been approved by the United States Food and Drug Administration (FDA) in children less than 2 years old.

This study has about 4 study visits that last over about 18 days.

Study Eligibility

Male or female birth to less than 2 years old with suspected or confirmed gram negative infection.

Contact

For more information about this study, contact Natalie James at 501-364-2251 or jamesnr@archildrens.org